Endoscopic radiofrequency ablation for malignant biliary strictures

  • Authors:
    • Fei Wang
    • Quanpeng Li
    • Xiuhua Zhang
    • Guobing Jiang
    • Xianxiu Ge
    • Hong Yu
    • Junjie Nie
    • Guozhong Ji
    • Lin Miao
  • View Affiliations

  • Published online on: April 6, 2016     https://doi.org/10.3892/etm.2016.3235
  • Pages: 2484-2488
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endoscopic radiofrequency ablation (RFA) is a novel palliation therapy for malignant biliary stricture; however, its feasibility and safety has not yet been clearly defined. The aim of the present study was to evaluate the feasibility and safety of endoscopic RFA for the treatment of malignant biliary strictures. A total of 12 patients treated by endoscopic RFA between December 2011 and October 2013 were retrospectively analyzed. Adverse events within 30 days post‑intervention, stricture diameters prior to and following RFA, stent patency and survival time were investigated. A total of 12 patients underwent 20 RFA procedures as a treatment for malignant biliary strictures. Two patients required repeated elective RFA (4 and 6 times, respectively). All 20 RFA procedures were successfully performed without technical problems. During a 30 day period following each RFA procedure, two patients experienced fever (38.2 and 38.9˚C, respectively) and another patient exhibited post‑endoscopic retrograde cholangiopancreatography pancreatitis. The 30‑ and 90‑day mortality rates were 0 and 8.3%, respectively. Mean stricture diameter prior to RFA was 5.3 mm (standard deviation (SD), 0.9 mm; range, 5‑8 mm), and the mean diameter following RFA was 12.6 mm (SD, 3.1 mm; range, 8‑15 mm). There was a significant increase of 7.3 mm in the bile duct diameter following RFA in comparison with prior to RFA (t=8.6; P≤0.001). Of the 11 patients with stents inserted following RFA, the median stent patency was 125.0 days [95% confidence interval (CI), 94.7‑155.3 days]. Extrapolated median survival following the first RFA was 232 days (95% CI, 94.3‑369.7 days). In conclusion, RFA appears to be an efficient and safe treatment strategy for the palliation of unresectable malignant biliary strictures.
View Figures
View References

Related Articles

Journal Cover

June-2016
Volume 11 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang F, Li Q, Zhang X, Jiang G, Ge X, Yu H, Nie J, Ji G and Miao L: Endoscopic radiofrequency ablation for malignant biliary strictures. Exp Ther Med 11: 2484-2488, 2016
APA
Wang, F., Li, Q., Zhang, X., Jiang, G., Ge, X., Yu, H. ... Miao, L. (2016). Endoscopic radiofrequency ablation for malignant biliary strictures. Experimental and Therapeutic Medicine, 11, 2484-2488. https://doi.org/10.3892/etm.2016.3235
MLA
Wang, F., Li, Q., Zhang, X., Jiang, G., Ge, X., Yu, H., Nie, J., Ji, G., Miao, L."Endoscopic radiofrequency ablation for malignant biliary strictures". Experimental and Therapeutic Medicine 11.6 (2016): 2484-2488.
Chicago
Wang, F., Li, Q., Zhang, X., Jiang, G., Ge, X., Yu, H., Nie, J., Ji, G., Miao, L."Endoscopic radiofrequency ablation for malignant biliary strictures". Experimental and Therapeutic Medicine 11, no. 6 (2016): 2484-2488. https://doi.org/10.3892/etm.2016.3235